Primary Outcomes of the Esprit™ BTK Drug-Eluting Resorbable Scaffold for the Treatment of Infrapopliteal Lesions: The LIFE-BTK Randomized Controlled Trial

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Philips; Nectero; Intervene; Surmodics; Abbott; Medtronic; W.L. Gore & Associates; R3 Vascular; Vesteck; Bard Medical; Cook Medical
• Equity/Stock(s)/Options - Vesteck; EBR Systems